Dr Schuchter's research is focused on the development of new treatments for patients with melanoma in studies that focus on immunotherapy and targeted approaches. She has extensive experience in melanoma translational research, and thus serves as an important link between basic scientists and clinical investigators. She is the co-PI on the SPORE in Skin Cancer.
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015 Apr 16.
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012 Nov.
Survival in BRAF 4600-mutant advanced melanoma treated with venurafenib. N Engl J Med 2012 Feb 23.